593 Background: A Swedish national family-cancer database reported an association between renal cell carcinoma (RCC) and hematologic malignancies within families. Our hypothesis was that a search of a state cancer registry would detect an increased incidence of observed (versus expected) synchronous and metachronous cases of RCC and select hematologic malignancies. Methods: A query of the Mississippi Cancer Registry was performed for synchronous ( < 6 months between diagnoses) and metachronous ( > 6 months) cases of RCC and select hematologic malignancies (non-Hodgkin lymphoma (NHL), multiple myeloma (MM), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia, and Hodgkin lymphoma) in the state from 2003 to 2013. The expected number of cases was calculated based on crude case numbers available from https://www.cancer-rates.info/ms/. The percentage of the population < 18 years of age was removed from the eligible population. 2x2 tables were constructed to calculate a chi-square score of expected versus observed cases. Using one degree of freedom, a p-value was calculated from this statistic. Due to privacy issues, the registry was unable to provide an exact number of observed combined cases if there were < 5 in the time period. Results: Conclusions: There is a statistically significantly increased incidence of observed (versus expected) synchronous and metachronous cases of RCC with the B-cell malignancies NHL, MM, and CLL in Mississippi between 2003 and 2013. Future research will focus on clinical characteristics of patients with synchronous or metachronous cases of RCC and these hematologic malignancies.[Table: see text]
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.